title: A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
abstract: The available literature provides few studies on the effectiveness of methylphenidate in improving quality of life in individuals with ADHD.
  
  
  OBJECTIVE
  To assess the effectiveness of methylphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD.
  
  
  METHODS
  A 12-week, multicenter, open-label trial involving 60 patients was used. The measures used were Adult Self-Rating Scale, Adult ADHD Quality of Life Scale (AAQoL), State and Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression (CGI), and safety measures. A significance statistic level of 5% was adopted.
  
  
  RESULTS
  Analyses included 60 patients (66.7% male; M age = 31.1 years) for safety and 58 patients for effectiveness. All AAQoL subscales improved from baseline to Week 12 (p < .0001), as well as the Total AAQoL (p < .0001). A significant reduction on Clinical Global Impression-Improvement (CGI-I), HAM-D, STAI, and ASRS scores was observed (p < .0001). No serious adverse event was reported.
  
  
  CONCLUSIONS
  Treatment of adult ADHD patients with OROS MPH improves QoL.
authors.affiliation: Institute D'Or of Research and Learning, Universidade Federal do Rio de Janeiro, Brazil. paulomattos@ufrj.br
authors.forename: Paulo
authors.initials: P
authors.lastname: Mattos
authors.forename: Mário Rodrigues
authors.initials: MR
authors.lastname: Louzã
authors.forename: André Luís Fernandes
authors.initials: AL
authors.lastname: Palmini
authors.forename: Irismar Reis
authors.initials: IR
authors.lastname: de Oliveira
authors.forename: Fábio Lopes
authors.initials: FL
authors.lastname: Rocha
mesh_terms: D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology*; D001938:Brazil; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use*; D010555:Personality Inventory / Q000706:statistics & numerical data; D011788:Quality of Life / Q000523:psychology*
chemical_list: D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D008774:Methylphenidate